Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 3/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL327825 | 1.00 | CTSK (0.53) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL2058674 | 1.00 | CTSK (0.53) | CTSKCA1CA2CA7CYP2D6 | |
| Butanal SCHEMBL5945901 | 0.87 | CTSK (0.47) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL28211162 | 0.84 | CTSK (0.56) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL19489244 | 0.83 | CA1 (0.50) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL12319265 | 0.83 | CA1 (0.50) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL4117634 | 0.82 | CA1 (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL12634867 | 0.82 | CA1 (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL12634863 | 0.82 | CA1 (0.49) | CTSKCA1CA2CA7CYP2D6 | |
| SCHEMBL13365447 | 0.81 | CTSK (0.54) | CTSKCA1CA2CA7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA, INC. (US) | 2019-04-30 | — | — | US | claimed |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. | 2017-09-14 | — | — | US | claimed |
| EP-2998329-A2 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2016-03-23 | — | — | EP | claimed |
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2016-02-25 | — | — | US | claimed |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC, | 2014-10-16 | — | — | US | claimed |
| EP-2539380-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2013-01-02 | — | — | EP | claimed |
| WO-2011106542-A2 | CROSSLINKED POLYVRNYLAMINE, POLY ALL YLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2011-09-01 | — | — | WO | claimed |
| US-20070129383-A1 | Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-06-07 | — | — | US | claimed |
| EP-1674454-A1 | SUBSTITUTED 2-AMINO- 1,2,4 TRIAZOLO 1,5-a PYRIMIDINE DERIVATIVE AND USE THEREOF | Nippon Kayaku Kabushiki Kaisha (JP) | 2006-06-28 | — | — | EP | claimed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3455234-B1 | SECO MACROLIDE COMPOUNDS | SELVITA D O O (HR) | 2026-04-01 | — | — | EP | disclosed |
| US-12590096-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists | BeOne Medicines | GmbH (CH) | 2026-03-31 | — | — | US | disclosed |
| US-20260027118-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-0259835-B1 | PYRIDAZINONE DERIVATIVES | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| WO-1991018866-A2 | 1,4-DIAMINO-2,3-DIHYDROXYBUTANES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1991-12-12 | — | — | WO | disclosed |
| US-5049558-A | Quaternized nitrogen-heterocycle substituted | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-09-17 | — | — | US | disclosed |
| EP-0164944-B1 | CEPHALOSPORIN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-07-11 | — | — | EP | disclosed |
| EP-0259835-A2 | Pyridazinone derivatives | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1988-03-16 | — | — | EP | disclosed |
| EP-0164944-A1 | Cephalosporin derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001889-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | CTSK 4670/4885CA1 4158/4885CA2 4095/4885 |
| US-20160051576-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, GPBAR1 | CTSK 4156/4885CA1 4464/4885CA2 4395/4885 |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, SLC10A1 | CTSK 3267/4885CA1 4256/4885CA2 3436/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | CTSK 2087/4885CA1 2085/4885CA2 3450/4885 |
| US-20070129383-A1 | Substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrimidine derivative and use thereof | ADORA1, ADORA2B, ADORA3 | CTSK 3955/4885CA1 3471/4885CA2 1359/4885 |
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | NR1H4, SLC10A2, GPBAR1 | CTSK 4156/4885CA1 4464/4885CA2 4395/4885 |
| US-20140309192-A1 | MODULATORS OF THE G PROTEIN-COUPLED MAS RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | MRGPRX1, MRGPRX2, AGTR1 | CTSK 2078/4885CA1 1094/4885CA2 365/4885 |
| US-12590096-B2 | Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists | TLR8, TLR7, TLR1 | CTSK 4471/4885CA1 3788/4885CA2 1785/4885 |
| US-20260027118-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SF3B1, SF3A1, SF3B5 | CTSK 4612/4885CA1 4242/4885CA2 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.